Production (Stage)
Cellectar Biosciences, Inc.
CLRB
$0.3822
-$0.031-7.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -24.54M | -44.58M | -50.11M | -52.96M | -62.22M |
| Total Depreciation and Amortization | 259.50K | 291.70K | 293.10K | 265.70K | 238.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -16.08M | -1.57M | 3.63M | 9.09M | 23.12M |
| Change in Net Operating Assets | -3.24M | -1.73M | -78.90K | -1.56M | 304.50K |
| Cash from Operations | -43.60M | -47.58M | -46.27M | -45.17M | -38.55M |
| Capital Expenditure | -82.60K | -104.20K | -309.70K | -907.00K | -885.70K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -82.60K | -104.20K | -309.70K | -907.00K | -885.70K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 17.56M | 61.41M | 84.00M | 66.79M | 66.79M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | 22.15M | 22.15M |
| Repurchase of Preferred Stock | -- | -- | -22.15M | -22.15M | -22.15M |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 17.56M | 61.41M | 61.85M | 66.79M | 66.79M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -26.13M | 13.72M | 15.28M | 20.72M | 27.35M |